View:
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
 |
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
INVIVO THERAPEUTICS HOLDINGS CORP. [ NVIV ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 12/29/2011 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
|||||||||||||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| COMMON STOCK, $0.00001 PAR VALUE | 12/29/2011 | S | 165,247 | D | $2.489(1) | 8,097,113 | D | |||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Explanation of Responses: |
| 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.45 to $2.66, inclusive. The reporting person undertakes to provide InVivo Therapeutics Holdings Corp. ("InVivo"), any security holder of InVivo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1. |
| /S/ ELIZABETH FRASER, ATTORNEY-IN-FACT | 01/03/2012 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
Power of Attorney
I, Robert Langer, the undersigned, hereby constitute and appoint Bradley Jacobson, Robert Puopolo,
Elizabeth Fraser, and Abdullah Malik, and each of them individually, as my true and lawful
attorney-in-fact to:
1. Complete and execute on my behalf, as a stockholder and member of the Scientific Advisory Board
of InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), Forms 3, 4, or
5 required to be filed by me under Section 16(a) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”) and the rules and regulations thereunder;
2. Do and perform any and all acts for and on my behalf which may be necessary or desirable to
complete and execute any such Forms 3, 4 or 5 and timely file such forms with the U.S. Securities
and Exchange Commission and any stock exchange or similar authority; and
3. Take any other action of any type whatsoever in connection with the foregoing, which in the
opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required
of me, it being understood that the documents executed by such attorney-in-fact on my behalf
pursuant to this Power of Attorney shall be in such form and shall contain such information as such
attorney-in-fact may approve in such attorney-in-fact’s discretion.
I hereby grant to each of such attorneys-in-fact full power and authority to do and perform all and
every act which is necessary, proper or desirable to be done in the exercise of any of the rights,
powers and authority granted in this Power of Attorney, with full power of substitution and
revocation, and I ratify and confirm every act that such attorney-in-fact lawfully performs or
causes to be done by virtue of this Power of Attorney and the powers and authority granted herein.
I acknowledge that the attorneys-in-fact appointed in this Power of Attorney, in serving in such
capacity at my request, are not assuming, and the Company is not assuming, any of my
responsibilities to comply with Section 16 of the Exchange Act or the rules or regulations
thereunder.
This Power of Attorney shall remain in full force and effect until I am no longer required to file
Forms 3, 4 or 5 with respect to my holdings or transactions in securities issued by the Company,
unless I earlier revoke this Power of Attorney in a signed writing delivered to the foregoing
attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of
December 30, 2011.
December 30, 2011.
/s/ Robert Langer
Print Name: Robert Langer